Syncona completed the acquisition of a 60.9% stake in Yellowstone Biosciences for £16.5m.

Syncona, a life science investor, completed the acquisition of a 60.9% stake in Yellowstone Biosciences, an oncology company pioneering soluble bispecific TCR-based therapies, for £16.5m. “Frequently expressed antigens that can be targeted therapeutically are notoriously difficult to find but, through two decades of research, we have identified a new class of targets that have potential to treat cancer and extend patient lives. We believe that our technology has the potential to selectively kill tumour cells, whilst sparing healthy cells, in a range of cancers. The strategy that we have built alongside Syncona, will initially focus on developing highly selective TCR-based therapies for AML, where we have formidable experience and data. Beyond that, we are committed to broadening our pipeline to other cancer settings to maximise Yellowstone’s potential,” Paresh Vyas, Yellowstone Co-founder and Chief Scientific Officer.